PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30957417-9 2019 Furthermore, we confirmed that PPARalpha and PPARgamma activation by WY14643 and pioglitazone, respectively, alleviated oleate-induced accumulation of total cholesterol, esterified cholesterol and neutral lipids by accelerating ABC transporter A1/G1-mediated cholesterol efflux. Cholesterol 157-168 peroxisome proliferator activated receptor alpha Mus musculus 31-40 31055081-6 2019 Asx/Bex promoted cholesterol efflux, partly via PPARalpha/RXR activation, while cholesterol biosynthesis/esterification was suppressed. Cholesterol 17-28 peroxisome proliferator activated receptor alpha Mus musculus 48-57 30957417-9 2019 Furthermore, we confirmed that PPARalpha and PPARgamma activation by WY14643 and pioglitazone, respectively, alleviated oleate-induced accumulation of total cholesterol, esterified cholesterol and neutral lipids by accelerating ABC transporter A1/G1-mediated cholesterol efflux. Cholesterol 181-192 peroxisome proliferator activated receptor alpha Mus musculus 31-40 30957417-9 2019 Furthermore, we confirmed that PPARalpha and PPARgamma activation by WY14643 and pioglitazone, respectively, alleviated oleate-induced accumulation of total cholesterol, esterified cholesterol and neutral lipids by accelerating ABC transporter A1/G1-mediated cholesterol efflux. Cholesterol 181-192 peroxisome proliferator activated receptor alpha Mus musculus 31-40 30504232-9 2019 This genome-wide profiling of lncRNAs in HFD-fed mice reveals one lncRNA, NONMMUG027912, which is potentially regulated by PPARalpha and is implicated in the process of cholesterol biosynthesis. Cholesterol 169-180 peroxisome proliferator activated receptor alpha Mus musculus 123-132 31933883-4 2019 We found that both triglyceride (TG) and total cholesterol (TC) uptake were inhibited in the intestine of ApcMin/+ mice with age and the intestinal peroxisome proliferator-activated receptor alpha (PPARalpha) downregulated the processes of beta-oxidation, oxidative stress response, and cholesterol absorption in APC-deficient mice. Cholesterol 47-58 peroxisome proliferator activated receptor alpha Mus musculus 148-196 31933883-4 2019 We found that both triglyceride (TG) and total cholesterol (TC) uptake were inhibited in the intestine of ApcMin/+ mice with age and the intestinal peroxisome proliferator-activated receptor alpha (PPARalpha) downregulated the processes of beta-oxidation, oxidative stress response, and cholesterol absorption in APC-deficient mice. Cholesterol 287-298 peroxisome proliferator activated receptor alpha Mus musculus 148-196 30592221-11 2019 INS feeding significantly upregulated various genes of cholesterol and bile acid metabolism, such as Srebp2, Hmgcr, Ldlr, Cyp7a1, Pparalpha, Fxr, and Pxr, in the liver. Cholesterol 55-66 peroxisome proliferator activated receptor alpha Mus musculus 130-139 30271349-9 2018 HDL-C increased by 40 and 80% in LXR and PPAR-alpha treated apoA-I transgenic mice, respectively, with 80% increase in fecal cholesterol. Cholesterol 125-136 peroxisome proliferator activated receptor alpha Mus musculus 41-51 30341732-0 2019 Peroxisome proliferator-activated receptor alpha attenuates high-cholesterol diet-induced toxicity and pro-thrombotic effects in mice. Cholesterol 65-76 peroxisome proliferator activated receptor alpha Mus musculus 0-48 30341732-1 2019 Peroxisome proliferator-activated receptor alpha (PPARalpha) is involved in the regulation of fatty acid and cholesterol metabolism. Cholesterol 109-120 peroxisome proliferator activated receptor alpha Mus musculus 0-48 30341732-1 2019 Peroxisome proliferator-activated receptor alpha (PPARalpha) is involved in the regulation of fatty acid and cholesterol metabolism. Cholesterol 109-120 peroxisome proliferator activated receptor alpha Mus musculus 50-59 30271349-10 2018 A fivefold increase in fecal cholesterol with no correlation with either plasma HDL-C or CEC following co-treatment with LXR and PPAR-alpha agonists suggested existence of an HDL-independent pathway for body cholesterol elimination. Cholesterol 208-219 peroxisome proliferator activated receptor alpha Mus musculus 129-139 30271349-11 2018 In hyperlipidemic diabetic ob/ob mice also combination of LXR and PPAR-alpha agonists showed marked increases in fecal cholesterol content (10-20-fold), while HDL-C rise was only 40%, further suggesting HDL-independent elimination of body cholesterol in mice treated with combination of LXR and PPAR-alpha agonists. Cholesterol 119-130 peroxisome proliferator activated receptor alpha Mus musculus 66-76 30271349-11 2018 In hyperlipidemic diabetic ob/ob mice also combination of LXR and PPAR-alpha agonists showed marked increases in fecal cholesterol content (10-20-fold), while HDL-C rise was only 40%, further suggesting HDL-independent elimination of body cholesterol in mice treated with combination of LXR and PPAR-alpha agonists. Cholesterol 239-250 peroxisome proliferator activated receptor alpha Mus musculus 66-76 30271349-12 2018 Atherosclerosis attenuation by LXR and PPAR-alpha agonists in LDLr-deficient mice was associated with increased fecal cholesterol, but not HDL-C. Cholesterol 118-129 peroxisome proliferator activated receptor alpha Mus musculus 39-49 29352300-0 2018 5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARgamma and PPARalpha. Cholesterol 68-79 peroxisome proliferator activated receptor alpha Mus musculus 138-147 30001434-0 2018 Retraction: 5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARgamma and PPARalpha. Cholesterol 80-91 peroxisome proliferator activated receptor alpha Mus musculus 150-159 29960113-8 2018 In contrast, OLE had no effect in Ppara-null mice, indicating a direct involvement of PPARalpha in the OLE-induced serum TG and cholesterol reduction. Cholesterol 128-139 peroxisome proliferator activated receptor alpha Mus musculus 86-95 29112762-12 2018 In conclusion, PFNA produced cholestasis in mouse liver, and the activation of PPARalpha plays a central role in regulating BA and cholesterol metabolism and transport in mouse serum and liver. Cholesterol 131-142 peroxisome proliferator activated receptor alpha Mus musculus 79-88 26838045-9 2016 Collectively, these results suggest a critical role for PPARalpha in 2,4-D-induced testicular toxicity due to disruption of cholesterol/testosterone homeostasis in Leydig cells. Cholesterol 124-135 peroxisome proliferator activated receptor alpha Mus musculus 56-65 26838045-0 2016 PPARalpha-dependent cholesterol/testosterone disruption in Leydig cells mediates 2,4-dichlorophenoxyacetic acid-induced testicular toxicity in mice. Cholesterol 20-31 peroxisome proliferator activated receptor alpha Mus musculus 0-9 28855656-1 2017 Peroxisome-proliferator-activated receptor alpha (PPARalpha) and sterol regulatory element-binding protein (SREBP) play a role in regulating cellular fatty acid and cholesterol homeostasis via fatty acid oxidation and lipogenesis. Cholesterol 165-176 peroxisome proliferator activated receptor alpha Mus musculus 0-48 28855656-1 2017 Peroxisome-proliferator-activated receptor alpha (PPARalpha) and sterol regulatory element-binding protein (SREBP) play a role in regulating cellular fatty acid and cholesterol homeostasis via fatty acid oxidation and lipogenesis. Cholesterol 165-176 peroxisome proliferator activated receptor alpha Mus musculus 50-59 28082284-8 2017 Agonist-treated Ppara Hep mice had elevated serum cholesterol, phospholipids, and triglycerides when compared with Ppara-/- mice, indicating a possible role for extrahepatic PPARA in regulating circulating lipid levels. Cholesterol 50-61 peroxisome proliferator activated receptor alpha Mus musculus 16-21 27229177-7 2016 We further investigated the effect of NAMPT knockdown on the PPARalpha-LXRalpha pathway of cholesterol metabolism with MK886 (a selective inhibitor of PPARalpha) in RAW264.7 macrophages. Cholesterol 91-102 peroxisome proliferator activated receptor alpha Mus musculus 61-70 22129452-1 2011 BACKGROUND: Synthetic activators of peroxisome proliferator-activated receptors (PPARs) stimulate cholesterol removal from macrophages through PPAR-dependent up-regulation of liver x receptor alpha (LXRalpha) and subsequent induction of cholesterol exporters such as ATP-binding cassette transporter A1 (ABCA1) and scavenger receptor class B type 1 (SR-BI). Cholesterol 98-109 peroxisome proliferator activated receptor alpha Mus musculus 81-85 23220585-8 2013 Down-regulation of PPARalpha target genes suggested modulation of cholesterol absorption by intestinal ATGL. Cholesterol 66-77 peroxisome proliferator activated receptor alpha Mus musculus 19-28 22098164-12 2012 CONCLUSIONS: Inflammation disrupted PPAR-LXR-CYP7A1/ABCA1-mediated bile acid synthesis and cholesterol efflux resulting in exacerbated cholesterol accumulation in livers of C57BL/6J mice and HepG2 cells. Cholesterol 135-146 peroxisome proliferator activated receptor alpha Mus musculus 36-40 22207087-11 2012 Afterwards the cholesterol metabolism was studied in the liver especially focused on the gene expressions of cholesterol-catabolising enzymes (CYP7A1, CYP27A1 and CYP7B1), as well as those of associated nuclear receptors (LXRalpha, FXR, PPARalpha, and SREBP 2). Cholesterol 15-26 peroxisome proliferator activated receptor alpha Mus musculus 237-246 23967086-3 2013 Importantly, PPARalpha agonists are effective in raising HDL-cholesterol and lowering triglycerides, properties that reduce the risk for cardiovascular diseases. Cholesterol 61-72 peroxisome proliferator activated receptor alpha Mus musculus 13-22 22129452-1 2011 BACKGROUND: Synthetic activators of peroxisome proliferator-activated receptors (PPARs) stimulate cholesterol removal from macrophages through PPAR-dependent up-regulation of liver x receptor alpha (LXRalpha) and subsequent induction of cholesterol exporters such as ATP-binding cassette transporter A1 (ABCA1) and scavenger receptor class B type 1 (SR-BI). Cholesterol 237-248 peroxisome proliferator activated receptor alpha Mus musculus 81-85 22129452-6 2011 Pre-treatment of cells with a selective PPARalpha or PPARgamma antagonist completely abolished the effects of 13-HODE on cholesterol efflux and protein levels of genes investigated. Cholesterol 121-132 peroxisome proliferator activated receptor alpha Mus musculus 40-49 22129452-8 2011 CONCLUSION: 13-HODE induces cholesterol efflux from macrophages via the PPAR-LXRalpha-ABCA1/SR-BI-pathway. Cholesterol 28-39 peroxisome proliferator activated receptor alpha Mus musculus 72-76 18086530-13 2008 Treatment of N2a cells with LXR, RXR or PPAR agonists strongly stimulated cellular cholesterol efflux to HDL and reduced cellular cholesterol and beta-/gamma-secretase activities. Cholesterol 83-94 peroxisome proliferator activated receptor alpha Mus musculus 40-44 21441141-1 2011 OBJECTIVE: Peroxisome proliferator-activated receptor-alpha (PPARalpha) activation has been shown in vitro to increase macrophage cholesterol efflux, the initial step in reverse cholesterol transport (RCT). Cholesterol 130-141 peroxisome proliferator activated receptor alpha Mus musculus 61-70 21441141-1 2011 OBJECTIVE: Peroxisome proliferator-activated receptor-alpha (PPARalpha) activation has been shown in vitro to increase macrophage cholesterol efflux, the initial step in reverse cholesterol transport (RCT). Cholesterol 178-189 peroxisome proliferator activated receptor alpha Mus musculus 11-59 21441141-1 2011 OBJECTIVE: Peroxisome proliferator-activated receptor-alpha (PPARalpha) activation has been shown in vitro to increase macrophage cholesterol efflux, the initial step in reverse cholesterol transport (RCT). Cholesterol 178-189 peroxisome proliferator activated receptor alpha Mus musculus 61-70 21441141-7 2011 In concert, the PPARalpha agonist promoted cholesterol efflux and ATP binding cassette transporter A1/G1 expression in primary macrophages, and this was also by the PPARalpha-LXR pathway. Cholesterol 43-54 peroxisome proliferator activated receptor alpha Mus musculus 16-25 21126601-2 2011 These drugs act as PPARalpha agonists and upregulate the expression of genes crucial in reverse cholesterol transport (RCT). Cholesterol 96-107 peroxisome proliferator activated receptor alpha Mus musculus 19-28 19960455-7 2010 Hereby, we identified Q(10)H(2)-sensitive genes which are regulated by peroxisome proliferator-activated receptor-alpha and are primarily involved in cholesterol synthesis (e.g. HMGCS1, HMGCL and HMGCR), fat assimilation (FABP5), lipoprotein metabolism (PLTP) and inflammation (STAT-1). Cholesterol 150-161 peroxisome proliferator activated receptor alpha Mus musculus 71-119 21088444-7 2010 In cells transfected with a specific peroxisome proliferator-activated receptor (PPAR)-alpha small interfering RNA, the induction of ABCA1 expression and apoA-I-mediated 3H-cholesterol efflux by aspirin were substantially suppressed. Cholesterol 173-184 peroxisome proliferator activated receptor alpha Mus musculus 81-92 19067122-0 2009 Effects of high dietary fat and cholesterol on expression of PPAR alpha, LXR alpha, and their responsive genes in the liver of apoE and LDLR double deficient mice. Cholesterol 32-43 peroxisome proliferator activated receptor alpha Mus musculus 61-71 18773970-7 2008 These data demonstrate a tight interrelationship between induction of PPAR alpha by endogenous ligands and up-regulation of genes of cholesterol biosynthesis through increased expression of SREBP2. Cholesterol 133-144 peroxisome proliferator activated receptor alpha Mus musculus 70-80 18758514-3 2008 Activators of peroxisome proliferator-activated receptor gamma (PPARgamma), as well as PPARalpha, increase expression of liver X receptor alpha (LXRalpha) in macrophages and promote the expression of ABCA1, which, in turn, mediates cholesterol efflux to apoA1. Cholesterol 232-243 peroxisome proliferator activated receptor alpha Mus musculus 87-96 18498712-3 2008 Peroxisome proliferator-activated receptor alpha (PPARalpha) can increase expression of liver X receptor alpha (LXRalpha) in macrophages and thereby promote the expression of ABCA1, which, in turn, mediates cholesterol efflux to apoA1. Cholesterol 207-218 peroxisome proliferator activated receptor alpha Mus musculus 0-48 18498712-3 2008 Peroxisome proliferator-activated receptor alpha (PPARalpha) can increase expression of liver X receptor alpha (LXRalpha) in macrophages and thereby promote the expression of ABCA1, which, in turn, mediates cholesterol efflux to apoA1. Cholesterol 207-218 peroxisome proliferator activated receptor alpha Mus musculus 50-59 21441141-0 2011 Peroxisome proliferator-activated receptor-alpha activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Cholesterol 88-99 peroxisome proliferator activated receptor alpha Mus musculus 0-48 21441141-1 2011 OBJECTIVE: Peroxisome proliferator-activated receptor-alpha (PPARalpha) activation has been shown in vitro to increase macrophage cholesterol efflux, the initial step in reverse cholesterol transport (RCT). Cholesterol 130-141 peroxisome proliferator activated receptor alpha Mus musculus 11-59 19930639-13 2009 CONCLUSION: Together these data showed that the PPARalpha agonist ciprofibrate stimulates CETP gene expression and changes the cholesterol flow through the reverse cholesterol transport, increasing plasma cholesterol removal through LDL. Cholesterol 127-138 peroxisome proliferator activated receptor alpha Mus musculus 48-57 19930639-13 2009 CONCLUSION: Together these data showed that the PPARalpha agonist ciprofibrate stimulates CETP gene expression and changes the cholesterol flow through the reverse cholesterol transport, increasing plasma cholesterol removal through LDL. Cholesterol 164-175 peroxisome proliferator activated receptor alpha Mus musculus 48-57 19930639-13 2009 CONCLUSION: Together these data showed that the PPARalpha agonist ciprofibrate stimulates CETP gene expression and changes the cholesterol flow through the reverse cholesterol transport, increasing plasma cholesterol removal through LDL. Cholesterol 164-175 peroxisome proliferator activated receptor alpha Mus musculus 48-57 19220285-9 2009 CONCLUSIONS AND IMPLICATIONS: Dual PPARalpha/gamma agonism with tesaglitazar markedly improved the atherogenic triad by reducing triglycerides and very low-density lipoprotein-cholesterol and increasing high-density lipoprotein-cholesterol and additionally reduced cholesterol-induced vessel wall activation. Cholesterol 176-187 peroxisome proliferator activated receptor alpha Mus musculus 35-44 18769950-1 2008 Synthetic activators of peroxisome proliferator-activated receptors (PPAR)-alpha and -gamma are capable of reducing macrophage foam cell cholesterol accumulation through the activation of genes involved in cholesterol homeostasis. Cholesterol 137-148 peroxisome proliferator activated receptor alpha Mus musculus 69-80 18769950-1 2008 Synthetic activators of peroxisome proliferator-activated receptors (PPAR)-alpha and -gamma are capable of reducing macrophage foam cell cholesterol accumulation through the activation of genes involved in cholesterol homeostasis. Cholesterol 206-217 peroxisome proliferator activated receptor alpha Mus musculus 69-80 18489776-9 2008 Functional implications inferred form our data suggested that nutrient-activated PPARalpha regulated transporters and phase I/II metabolic enzymes were involved in a) fatty acid oxidation, b) cholesterol, glucose, and amino acid transport and metabolism, c) intestinal motility, and d) oxidative stress defense. Cholesterol 192-203 peroxisome proliferator activated receptor alpha Mus musculus 81-90 18086530-13 2008 Treatment of N2a cells with LXR, RXR or PPAR agonists strongly stimulated cellular cholesterol efflux to HDL and reduced cellular cholesterol and beta-/gamma-secretase activities. Cholesterol 130-141 peroxisome proliferator activated receptor alpha Mus musculus 40-44 17724261-7 2007 Peritoneal macrophages from PPARalpha(-/-) mice had increased uptake of oxidized LDL and decreased cholesterol efflux. Cholesterol 99-110 peroxisome proliferator activated receptor alpha Mus musculus 28-37 17726195-0 2007 Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. Cholesterol 31-42 peroxisome proliferator activated receptor alpha Mus musculus 58-67 17726195-2 2007 Treatment with PPARalpha agonists enhances fatty acid oxidation, decreases plasma triglycerides, and may promote reverse cholesterol transport. Cholesterol 121-132 peroxisome proliferator activated receptor alpha Mus musculus 15-24 17726195-8 2007 These data demonstrate that fenofibrate specifically acts via PPARalpha to decrease cholesterol absorption at the level of intestinal NPC1L1 expression. Cholesterol 84-95 peroxisome proliferator activated receptor alpha Mus musculus 62-71 17214990-7 2007 These disparate effects were observed with the dual PPAR agonist despite lowering LDL cholesterol and improving insulin sensitivity to a similar extent to PPARalpha and gamma agonists used individually. Cholesterol 86-97 peroxisome proliferator activated receptor alpha Mus musculus 52-56 17724261-10 2007 CONCLUSIONS: These data demonstrate that PPARalpha expression by macrophages has antiatherogenic effects via modulation of cell cholesterol trafficking and inflammatory activity. Cholesterol 128-139 peroxisome proliferator activated receptor alpha Mus musculus 41-50 17495606-7 2007 Several of these cholesterol carriers influence intracellular cholesterol homeostasis and are controlled by transcription factors, including RXR, LXR, SREBP-2 and PPARalpha. Cholesterol 17-28 peroxisome proliferator activated receptor alpha Mus musculus 163-172 17014868-11 2006 In addition the dual activation of PPAR alpha/gamma also shows an athero-protective potential by inducing reverse cholesterol efflux and inhibiting the pro-inflammatory cytokines. Cholesterol 114-125 peroxisome proliferator activated receptor alpha Mus musculus 35-45 17118139-1 2006 BACKGROUND: Fibrates are a unique hypolipidemic drugs that lower plasma triglyceride and cholesterol levels through their action as peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. Cholesterol 89-100 peroxisome proliferator activated receptor alpha Mus musculus 132-180 17118139-1 2006 BACKGROUND: Fibrates are a unique hypolipidemic drugs that lower plasma triglyceride and cholesterol levels through their action as peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. Cholesterol 89-100 peroxisome proliferator activated receptor alpha Mus musculus 182-191 15878692-0 2005 Deficiency of PPARalpha disturbs the response of lipogenic flux and of lipogenic and cholesterogenic gene expression to dietary cholesterol in mouse white adipose tissue. Cholesterol 128-139 peroxisome proliferator activated receptor alpha Mus musculus 14-23 15878692-2 2005 Consumption of a high (2% w/w) cholesterol diet resulted in a further increase in the concentration of cholesterol and a further decrease in epididymal fat pad weight in PPARalpha-null mice, but had no effect in the wild-type. Cholesterol 31-42 peroxisome proliferator activated receptor alpha Mus musculus 170-179 15878692-4 2005 Adipose tissue de novo lipogenesis was increased in PPARalpha-null mice and was further enhanced when they were fed a cholesterol-rich diet; no such effect was observed in the wild-type mice. Cholesterol 118-129 peroxisome proliferator activated receptor alpha Mus musculus 52-61 15878692-6 2005 Consumption of a high-cholesterol diet increased the mRNA expression of these genes in the PPARalpha-deficient mice but not in the wild-type. Cholesterol 22-33 peroxisome proliferator activated receptor alpha Mus musculus 91-100 15878692-9 2005 The results suggest that PPARalpha plays a role in adipose tissue cholesterol and triacylglycerol homeostasis and prevents cholesterol-mediated changes in de novo lipogenesis. Cholesterol 66-77 peroxisome proliferator activated receptor alpha Mus musculus 25-34 15878692-9 2005 The results suggest that PPARalpha plays a role in adipose tissue cholesterol and triacylglycerol homeostasis and prevents cholesterol-mediated changes in de novo lipogenesis. Cholesterol 123-134 peroxisome proliferator activated receptor alpha Mus musculus 25-34 15867396-1 2005 Peroxisome proliferator-activated receptor (PPAR) represents a ligand-dependent nuclear receptor family that regulates multiple metabolic processes associated with fatty acid beta-oxidation, glucose utilization, and cholesterol transport. Cholesterol 216-227 peroxisome proliferator activated receptor alpha Mus musculus 0-42 15867396-1 2005 Peroxisome proliferator-activated receptor (PPAR) represents a ligand-dependent nuclear receptor family that regulates multiple metabolic processes associated with fatty acid beta-oxidation, glucose utilization, and cholesterol transport. Cholesterol 216-227 peroxisome proliferator activated receptor alpha Mus musculus 44-48 15946420-7 2005 Administration of fenofibrate, an agonist for PPARalpha, with a cholesterol diet caused marked hepatomegaly, an increase in plasma HDL-cholesterol, a decrease in hepatic cholesterol content, and alterations in hepatic mRNA levels similar to those observed in mice given IHE. Cholesterol 64-75 peroxisome proliferator activated receptor alpha Mus musculus 46-55 16054078-0 2005 "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cholesterol 70-81 peroxisome proliferator activated receptor alpha Mus musculus 28-37 16054078-7 2005 These results suggest that products of the FAS reaction regulate glucose, lipid, and cholesterol metabolism by serving as endogenous activators of distinct physiological pools of PPARalpha in adult liver. Cholesterol 85-96 peroxisome proliferator activated receptor alpha Mus musculus 179-188 15946420-7 2005 Administration of fenofibrate, an agonist for PPARalpha, with a cholesterol diet caused marked hepatomegaly, an increase in plasma HDL-cholesterol, a decrease in hepatic cholesterol content, and alterations in hepatic mRNA levels similar to those observed in mice given IHE. Cholesterol 135-146 peroxisome proliferator activated receptor alpha Mus musculus 46-55 15946420-7 2005 Administration of fenofibrate, an agonist for PPARalpha, with a cholesterol diet caused marked hepatomegaly, an increase in plasma HDL-cholesterol, a decrease in hepatic cholesterol content, and alterations in hepatic mRNA levels similar to those observed in mice given IHE. Cholesterol 135-146 peroxisome proliferator activated receptor alpha Mus musculus 46-55 15371561-1 2004 Lipid homeostasis is controlled in part by the nuclear receptors peroxisome proliferator (PP)-activated receptor alpha (PPARalpha) and liver X receptor (LXR) through regulation of genes involved in fatty acid and cholesterol metabolism. Cholesterol 213-224 peroxisome proliferator activated receptor alpha Mus musculus 65-118 15371561-1 2004 Lipid homeostasis is controlled in part by the nuclear receptors peroxisome proliferator (PP)-activated receptor alpha (PPARalpha) and liver X receptor (LXR) through regulation of genes involved in fatty acid and cholesterol metabolism. Cholesterol 213-224 peroxisome proliferator activated receptor alpha Mus musculus 120-129 12511553-2 2003 They exert multiple effects on lipid metabolism by activating the peroxisome proliferator-activated receptor-alpha (PPAR-alpha), which controls the transcriptional regulation of genes involved in hepatic fatty acid, cholesterol, and lipoprotein metabolism. Cholesterol 216-227 peroxisome proliferator activated receptor alpha Mus musculus 116-126 12511553-2 2003 They exert multiple effects on lipid metabolism by activating the peroxisome proliferator-activated receptor-alpha (PPAR-alpha), which controls the transcriptional regulation of genes involved in hepatic fatty acid, cholesterol, and lipoprotein metabolism. Cholesterol 216-227 peroxisome proliferator activated receptor alpha Mus musculus 66-114 14960661-3 2004 Peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists are known to induce peroxisomal fatty acid beta-oxidation and also mediate HDL cholesterol metabolism. Cholesterol 149-160 peroxisome proliferator activated receptor alpha Mus musculus 0-48 14960661-3 2004 Peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists are known to induce peroxisomal fatty acid beta-oxidation and also mediate HDL cholesterol metabolism. Cholesterol 149-160 peroxisome proliferator activated receptor alpha Mus musculus 50-59 14960661-4 2004 We have explored the hypothesis that simultaneous activation of PPARalpha and LXR may lead to additive effects on HDL cholesterol elevation as well as attenuation of triglyceride accumulation. Cholesterol 118-129 peroxisome proliferator activated receptor alpha Mus musculus 64-73 12897186-0 2003 Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. Cholesterol 14-25 peroxisome proliferator activated receptor alpha Mus musculus 55-65 12897186-9 2003 These results suggest that PPAR alpha influences cholesterol absorption through modulating ABCA1 activity in the intestine by a mechanism involving LXR alpha. Cholesterol 49-60 peroxisome proliferator activated receptor alpha Mus musculus 27-37 11714852-4 2001 However, when fed a high fat diet, male PPARalpha-null mice displayed 2-fold higher serum levels of apoB and LDL cholesterol compared with male wild-type mice, but triglyceride levels were not affected. Cholesterol 113-124 peroxisome proliferator activated receptor alpha Mus musculus 40-49 12117567-6 2002 The LXRalpha:PPARalpha heterodimer may be important in coordinating the expression of genes that encode proteins involved in metabolism of fats and cholesterol. Cholesterol 148-159 peroxisome proliferator activated receptor alpha Mus musculus 13-22 35078048-0 2022 Discovery of (E)-4-styrylphenoxy-propanamide: A dual PPARalpha/gamma partial agonist that regulates high-density lipoprotein-cholesterol levels, modulates adipogenesis, and improves glucose tolerance in diet-induced obese mice. Cholesterol 125-136 peroxisome proliferator activated receptor alpha Mus musculus 53-62 11495927-7 2001 Constitutive differences in serum cholesterol and triglycerides in PPARalpha-null mice were found between genetic backgrounds. Cholesterol 34-45 peroxisome proliferator activated receptor alpha Mus musculus 67-76 11254743-5 2001 The diurnal variation in hepatic fatty acid and cholesterol synthesis was also abolished in the PPAR alpha-null animals and the variations in the concentration of plasma triacylglycerol, nonesterified fatty acids, and cholesterol were all attenuated. Cholesterol 48-59 peroxisome proliferator activated receptor alpha Mus musculus 96-106 11254743-5 2001 The diurnal variation in hepatic fatty acid and cholesterol synthesis was also abolished in the PPAR alpha-null animals and the variations in the concentration of plasma triacylglycerol, nonesterified fatty acids, and cholesterol were all attenuated. Cholesterol 218-229 peroxisome proliferator activated receptor alpha Mus musculus 96-106 11254743-6 2001 The failure of HMG-CoAR expression to increase during the feeding period in the PPAR alpha-null mice was associated with a decrease in hepatic nonesterified cholesterol content and an increase in cholesteryl ester compared with normal mice. Cholesterol 157-168 peroxisome proliferator activated receptor alpha Mus musculus 80-90 9341179-9 1997 These studies demonstrate that PPARalpha modulates basal levels of serum cholesterol, in particular high density lipoprotein cholesterol, and establish that fibrate-induced modulation in hepatic apolipoprotein A-I, C-III mRNA, and serum triglycerides observed in wild-type mice is mediated by PPARalpha. Cholesterol 73-84 peroxisome proliferator activated receptor alpha Mus musculus 31-40 35150895-7 2022 In the fasted state, gene expression analysis revealed modulation of PPARalpha and liver X receptor (LXR) target genes by an increased fatty acid release, whereas the decreased plasma cholesterol concentrations in refed mice were more likely due to changes in HDL synthesis and secretion. Cholesterol 184-195 peroxisome proliferator activated receptor alpha Mus musculus 69-78 10867000-3 2000 In addition, fibrates also lower serum cholesterol levels, suggesting a possible link between the PPARalpha and cholesterol metabolism. Cholesterol 39-50 peroxisome proliferator activated receptor alpha Mus musculus 98-107 10867000-3 2000 In addition, fibrates also lower serum cholesterol levels, suggesting a possible link between the PPARalpha and cholesterol metabolism. Cholesterol 112-123 peroxisome proliferator activated receptor alpha Mus musculus 98-107 35184357-10 2022 We showed that NR RORgamma functions as an essential mediator that facilitates the interaction of PPARalpha and SREBP2 to modulate the cholesterol biosynthesis genes expression. Cholesterol 135-146 peroxisome proliferator activated receptor alpha Mus musculus 98-107 31851938-6 2019 Furthermore, SIRT6 mediates PPARalpha inhibition of SREBP-dependent cholesterol and triglyceride synthesis. Cholesterol 68-79 peroxisome proliferator activated receptor alpha Mus musculus 28-37 33996254-9 2021 Collectively, HFD upregulates TRAF6 and ubiquitinates EZH2 to promote the miR-429-dependent inhibition of PPARalpha, leading to cholesterol accumulation in liver and the occurrence of fatty liver. Cholesterol 128-139 peroxisome proliferator activated receptor alpha Mus musculus 106-115 32822737-0 2020 Perfluorooctanoic acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARalpha mice fed an American diet. Cholesterol 109-120 peroxisome proliferator activated receptor alpha Mus musculus 155-164 32661772-0 2020 NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-alpha and LXR agonists. Cholesterol 55-66 peroxisome proliferator activated receptor alpha Mus musculus 107-117 32661772-3 2020 Co-treatment of ob/ob mice with PPAR-alpha (fenofibrate) and LXR (T0901317) agonists increased fecal cholesterol by 12-fold; PPAR-alpha and LXR agonists individually showed 2.6- and 4.0-fold fecal cholesterol excretion, respectively. Cholesterol 101-112 peroxisome proliferator activated receptor alpha Mus musculus 32-42 32661772-3 2020 Co-treatment of ob/ob mice with PPAR-alpha (fenofibrate) and LXR (T0901317) agonists increased fecal cholesterol by 12-fold; PPAR-alpha and LXR agonists individually showed 2.6- and 4.0-fold fecal cholesterol excretion, respectively. Cholesterol 197-208 peroxisome proliferator activated receptor alpha Mus musculus 32-42 32661772-4 2020 We investigated the mechanism of synergistic efficacy of PPAR-alpha and LXR agonists in fecal cholesterol excretion. Cholesterol 94-105 peroxisome proliferator activated receptor alpha Mus musculus 57-67 32661772-11 2020 PPAR-alpha agonist increased fecal cholesterol primarily by influencing TICE, while LXR agonist influenced fecal cholesterol excretion via both RCT and TICE mechanisms. Cholesterol 35-46 peroxisome proliferator activated receptor alpha Mus musculus 0-10 32661772-12 2020 Synergistic efficacy on fecal cholesterol excretion following co-treatment with PPAR-alpha and LXR agonists occurred through a combination of RCT, TICE, and the key enzyme in bile synthesis, cholesterol 7-alpha hydroxylase (cyp7a1). Cholesterol 30-41 peroxisome proliferator activated receptor alpha Mus musculus 80-90 32661772-13 2020 These results suggest that cholesterol efflux, biliary cholesterol excretion, and TICE collectively contributed to the 12-fold increases in the fecal cholesterol excretion in ob/ob mice co-treated with PPAR-alpha and LXR agonists. Cholesterol 27-38 peroxisome proliferator activated receptor alpha Mus musculus 202-212 32661772-13 2020 These results suggest that cholesterol efflux, biliary cholesterol excretion, and TICE collectively contributed to the 12-fold increases in the fecal cholesterol excretion in ob/ob mice co-treated with PPAR-alpha and LXR agonists. Cholesterol 55-66 peroxisome proliferator activated receptor alpha Mus musculus 202-212 32584895-3 2020 Pemafibrate is a novel selective PPARalpha modulator, which has been reported to improve atherogenic dyslipidemia, in particular, hypertriglyceridemia and low HDL-cholesterol. Cholesterol 163-174 peroxisome proliferator activated receptor alpha Mus musculus 33-42 32176696-0 2020 The PPAR pan-agonist tetradecylthioacetic acid promotes redistribution of plasma cholesterol towards large HDL. Cholesterol 81-92 peroxisome proliferator activated receptor alpha Mus musculus 4-8 33996254-8 2021 TRAF6 increased cholesterol accumulation in liver cells in vitro via the EZH2/miR-429/PPARalpha axis. Cholesterol 16-27 peroxisome proliferator activated receptor alpha Mus musculus 86-95 32687853-5 2020 These observations were correlated to cholesterol load in circulation in-vivo and we observed an inverse expression profile in mice models of atherosclerosis (ApoE-/-) and hyperlipidemia (PPARalpha-/-) in response to high cholesterol diet. Cholesterol 38-49 peroxisome proliferator activated receptor alpha Mus musculus 188-197 32687853-5 2020 These observations were correlated to cholesterol load in circulation in-vivo and we observed an inverse expression profile in mice models of atherosclerosis (ApoE-/-) and hyperlipidemia (PPARalpha-/-) in response to high cholesterol diet. Cholesterol 222-233 peroxisome proliferator activated receptor alpha Mus musculus 188-197 31607484-1 2019 The peroxisome proliferator-activated receptor (PPAR)-alpha agonist fenofibrate is used as a lipid-lowering agent to reduce cholesterol and triglyceride in blood. Cholesterol 124-135 peroxisome proliferator activated receptor alpha Mus musculus 4-59 31654746-8 2019 The protein-protein interaction (PPI) network and qPCR analyses further confirm that the PPAR signaling pathway and the ovarian infertility genes were also involved in blocking the cholesterol biosynthesis pathway. Cholesterol 181-192 peroxisome proliferator activated receptor alpha Mus musculus 89-93